2169946-15-8

2169946-15-8 structure

2169946-15-8 structure

Name: Zanidatamab
Chemical Name: Zanidatamab
CAS Number: 2169946-15-8
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways JAK/STAT Signaling EGFR
Create Date: 2023-02-05 12:15:40
Modify Date: 2024-04-05 16:37:18
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity[1].

Name	Zanidatamab

Description	Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
Target	HER2
In Vitro	Zanidatamab (ZW25) 对重组 HER2 和具有一定 HER2 表达的培养癌细胞具有低 nM 结合亲和力 (0.9-16 nM)[1]。 Zanidatamab 可抑制 HER2 广泛表达的人类癌细胞系的生长 (5-54% 的抑制取决于细胞系)，并抑制配体介导的肿瘤细胞增殖[1]。 Zanidatamab 在nM 浓度下 (0.05-64 nM) 诱导浓度依赖的 ADCC，在表达 HER2 的 TNBC 细胞系上最大裂解率可达 52%，并在各种 HER2 表达肿瘤细胞系中与多种化疗药物 (包括铂类、紫杉烷类、微管抑制剂和 DNA 合成抑制剂) 表现出协同作用[1]。
In Vivo	Zanidatamab (ZW25) 诱导显著的肿瘤消退，表现出相对于 hIgG 对照 307% 的肿瘤生长抑制和 70% 的完全消退率[1]。
References	[1]. Weisser N, et, al. Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers. Cancer Res. 2017:77 (13).

No Any Chemical & Physical Properties